Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Recruiting · NCT07517198 · Registry updated 2026-06-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Margins of Excision, Morphological and Microscopic Findings, Neoplasms by Histologic Type, Neoplasms by Site, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, head and neck squamous cell carcinoma, kidney cancer, kidney disorder, liver cancer, liver disorder, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, squamous cell carcinoma, stomach disorder, triple-negative breast carcinoma, urinary system disorder | Recruiting | Phase 1 | 2026-06-10 | NCT07517198 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 3 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| START Dallas | Fort Worth | United States | 4 |
| Start Lacn | Los Angeles | United States | 1 |
| START Mountain Region | West Valley City | United States | 46 |